We Celebrate >600,000 Views for our 2,830 Scientific Articles in Life Sciences and Medicine
Curator: Aviva Lev-Ari, PhD, RN
Top Posts >1,000 Views for all days from our Day 1:
4/12/2012 ending 2015-03-19 (Summarized)
AND
Top Authors VIEWS for all days ending 2015-03-19 (Summarized)
Top Authors for all days ending 2015-03-19 (Summarized)
All Time
Author | Views | ||
2012pharmaceutical – Aviva Lev-Ari, PhD, RN | 183,517 | ||
larryhbern – Larry H Bernstein, MD, FCAP | 95,888 | ||
tildabarliya – Tilda Barliya, PhD | 29,070 | ||
sjwilliamspa – Stephen J Williams, PhD | 17,346 | ||
Dr. Sudipta Saha – Sudipta Saha, PhD | 15,708 | ||
Dror Nir – Dror Nir, PhD | 15,247 | ||
ritusaxena – Ritu Saxena, PhD | 11,848 | ||
aviralvatsa – Aviral Vatsa, PhD | 6,469 | ||
Demet Sag, Ph.D., CRA, GCP | 5,824 | ||
zraviv06 – Ziv Raviv, PhD | 4,264 | ||
anamikasarkar – Anamika Sarkar, PhD | 2,739 | ||
zs22 – Zohi S. PhD | 2,380 | ||
pkandala – Praboda Kandala, PhD | 1,973 | ||
Alan F. Kaul, PharmD., MS, MBA, FCCP | 1,662 | ||
Aashir Awan, PhD | 1,229 | ||
megbaker58 – Meg Baker, PhD | 1,214 | ||
jdpmdphd – Justin D Perlman, MD, PhD, FACC |
750 |
||
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.